@article{cf250e1d389e485da840560c34d23c67,
title = "Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma",
abstract = "Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment1; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers.",
author = "Amaria, {Rodabe N.} and Reddy, {Sangeetha M.} and Tawbi, {Hussein A.} and Davies, {Michael A.} and Ross, {Merrick I.} and Glitza, {Isabella C.} and Cormier, {Janice N.} and Carol Lewis and Hwu, {Wen Jen} and Ehab Hanna and Adi Diab and Wong, {Michael K.} and Richard Royal and Neil Gross and Randal Weber and Lai, {Stephen Y.} and Richard Ehlers and Jorge Blando and Milton, {Den{\'a}i R.} and Scott Woodman and Robin Kageyama and Wells, {Daniel K.} and Patrick Hwu and Patel, {Sapna P.} and Anthony Lucci and Amy Hessel and Lee, {Jeffrey E.} and Jeffrey Gershenwald and Lauren Simpson and Burton, {Elizabeth M.} and Liberty Posada and Lauren Haydu and Linghua Wang and Shaojun Zhang and Lazar, {Alexander J.} and Hudgens, {Courtney W.} and Vancheswaran Gopalakrishnan and Alexandre Reuben and Andrews, {Miles C.} and Spencer, {Christine N.} and Victor Prieto and Padmanee Sharma and James Allison and Tetzlaff, {Michael T.} and Wargo, {Jennifer A.}",
note = "Funding Information: We thank the patients and their families for participating in this clinical trial. The clinical aspects of this study were funded by Bristol-Myers Squibb. The correlative research was supported by the philanthropic contributions to The University of Texas MD Anderson Cancer Center Melanoma Moon Shot Program, The Parker Institute for Cancer Immunotherapy and US Department of Defense Grant CA150619. Funding Information: R.N.A. received grants from Merck, Bristol-Myers Squibb and Array Biopharma, all outside the submitted work. S.M.R. received support from National Institutes of Health T32 Training Grant T32 CA 009666, outside the submitted work. H.A.T. received personal fees from Novartis, grants from Merck and Celgene, and grants and personal fees from BMS and Genentech, all outside of the submitted work. M.A.D. received personal fees from Novartis, BMS and Vaccinex, grants from AstraZeneca and Merck, and grants and personal fees from Roche/Genentech and Sanofi-Aventis, all outside the submitted work. W.-J.H. received research grants from Merck, Bristol-Myers Squibb, MedImmune, and GlaxoSmithKline and has served on an advisory board for Merck, all outside the submitted work. M.K.W. received personal fees from Merck and EMD Serono, outside the submitted work. J.G. has participated in the advisory board of Merck and Castle Biosciences. A.J.L. received personal fees from BMS, Novartis, Merck and Genentech/Roche, personal fees and nonfinancial support from ArcherDX and Beta-Cat, grants and nonfinancial support from Medimmune/AstraZeneca and Sanofi and grants, personal fees and nonfinancial support from Janssen, all outside the submitted work. V.G. reports a US patent (PCT/US17/53,717), consultant fees from Microbiome DX, and honoraria from CAP18, outside of the submitted work. A.R. reports a US patent (PCT/ US17/53,717) and is supported by the Kimberley Clark Foundation Award for Scientific Achievement provided by MD Anderson{\textquoteright}s Odyssey Fellowship Program. M.C.A. is supported by the National Health and Medical Research Council of Australia CJ Martin Early Career Fellowship (1148680), and reports advisory board participation, travel support and honoraria from Merck Sharpe and Dohme. C.N.S. reports a US patent (PCT/ US17/53,717), outside of the submitted work. P.S. received consultant or advisor fees from Bristol-Myers Squibb, GlaxoSmithKline, AstraZeneca, Amgen, Jounce, Kite Pharma, Neon, Evelo, EMD Serono and Astellas, during the conduct of the study; has stocks from Jounce, Kite Pharma, Evelo, Constellation and Neon, outside the submitted work; and has a patent licensed to Jounce, outside the submitted work. M.T.T. reports personal fees from Myriad Genetics, Seattle Genetics and Novartis, all outside the submitted work. J.A.W. reports a US patent (PCT/US17/53,717), has received compensation for speaker{\textquoteright}s bureau and honoraria from Dava Oncology, Bristol-Myers Squibb and Illumina and has served on advisory committees for GlaxoSmithKline, Roche/Genentech, Novartis and AstraZeneca. All other authors declare no competing interests. Publisher Copyright: {\textcopyright} 2018, The Author(s), under exclusive licence to Springer Nature America, Inc.",
year = "2018",
month = nov,
day = "1",
doi = "10.1038/s41591-018-0197-1",
language = "English (US)",
volume = "24",
pages = "1649--1654",
journal = "Nature medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "11",
}